{'fraction_non_alphanumeric': 0.037199124726477024, 'fraction_numerical': 0.0175054704595186, 'mean_word_length': 5.835820895522388, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
LL‐37 as a therapeutic target for late stage prostate cancer

The antimicrobial peptide, leucine–leucine‐37 (LL‐37), stimulates proliferation, angiogenesis, and cellular migration, inhibits apoptosis and is associated with inflammation. Since these functional processes are often exaggerated in cancer, the aim of the present study was to investigate the expression and role of LL‐37 in prostate cancer (PCa) and establish its value as a therapeutic target.